Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #7791
Reference
Drug alert 01/2023
Name
Drug alert class 4 drug alert 1 2023 – Class 4 medicines defect information – caution in use – Albireo AB Bylvay 1200 micrograms hard capsules
Categories
Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
DRUGS
SAFETY
RISKS
PHARMACEUTICAL INDUSTRY;
Description
Albireo AB has informed the MHRA that the side panel of the bottle label of the above batch of Bylvay 1200 micrograms Hard Capsules erroneously reflected the content of the active ingredient as 400 micrograms odevixibat (as sesquihydrate). This should state: “Each capsule contains 1200 micrograms odevixibat (as sesquihydrate)”.
Contact Name
Irene.Fazakerley
Contact Email
Contact Address
Medicines Policy Team Chief Medical Officer Directorate Pharmacy and Medicines Division St Andrew’s House, Regent Road, Edinburgh EH1 3DG
Contact Phone
Created
2023-01-03 00:00:00
Click to go back to homepage